Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 1;119(23):E1-3.
doi: 10.1002/cncr.27832. Epub 2012 Oct 5.

PD-1 targeting in cancer immunotherapy

Robert Ferris

PD-1 targeting in cancer immunotherapy

Robert Ferris. Cancer. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cancer immunotherapy is administered through antibody approaches to inhibit programmed cell death protein 1 (PD-1)/PD-L1 checkpoint receptor-ligand signaling to reactivate antitumor T cells. A blocking monoclonal antibody (MoAb) disrupts negative regulatory PD-1 signaling on tumor-infiltrating T lymphocytes, permitting effector T-cell activation in the tumor microenvironment, in which suppressive PD-L1 signals are mediated by intratumoral antigen-presenting cells (APC) or the tumor cells themselves. MHC indicates major histocompatibility complex; TCR, T cell receptor; CD4, cluster of differentiation 4; −, negative; +, positive; CD28, cluster of differentiation 28; CD8, cluster of differentiation 8. Expression of PD-L2 on tumor cells is currently under investigation.
See this image and copyright information in PMC

References

    1. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 2011;71:6567–6571. - PubMed
    1. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol Med. 2000;6:465–479. - PMC - PubMed
    1. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–1544. - PMC - PubMed
    1. Chapon M, Randriamampita C, Maubec E, et al. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol. 2011;131:1300–1307. - PubMed
    1. Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med. 2010;207:2175–2186. - PMC - PubMed

Publication types

MeSH terms

Substances